Drugs / BR-DIM
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02483624 | Jan 2016 | systemic lupus erythematosus | Northwell Health | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BR-DIM | “The DIM supplement to be used is BioResponse-DIM® (BR-DIM®), an absorption-enhanced formulation of proven bioavailability in animal testing and human trials.” NCT02483624 ↗ |
| Known as | BioResponse-DIM | “The DIM supplement to be used is BioResponse-DIM® (BR-DIM®), an absorption-enhanced formulation of proven bioavailability in animal testing and human trials.” NCT02483624 ↗ |
| Route | Oral | “BR-DIM or comparably packaged placebo will be administered orally with meals twice per day.” NCT02483624 ↗ |